COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 6,390,000 shares, an increase of 8.9% from the September 15th total of 5,870,000 shares. Based on an average daily volume of 516,300 shares, the short-interest ratio is presently 12.4 days.
Insider Buying and Selling at COMPASS Pathways
In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of COMPASS Pathways stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the sale, the insider now directly owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.25% of the company’s stock.
Hedge Funds Weigh In On COMPASS Pathways
Several large investors have recently modified their holdings of the business. Blue Trust Inc. purchased a new stake in COMPASS Pathways in the 2nd quarter valued at about $81,000. Green Alpha Advisors LLC acquired a new position in shares of COMPASS Pathways in the 3rd quarter worth approximately $99,000. Kennedy Capital Management LLC purchased a new position in shares of COMPASS Pathways during the 1st quarter worth approximately $139,000. Tidal Investments LLC increased its holdings in COMPASS Pathways by 43.6% in the 1st quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock valued at $159,000 after purchasing an additional 5,795 shares during the last quarter. Finally, Fore Capital LLC purchased a new stake in COMPASS Pathways in the second quarter valued at approximately $181,000. Institutional investors and hedge funds own 46.19% of the company’s stock.
COMPASS Pathways Trading Down 0.2 %
COMPASS Pathways (NASDAQ:CMPS – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03). During the same quarter in the previous year, the firm earned ($0.62) EPS. On average, research analysts predict that COMPASS Pathways will post -2.35 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $23.00 target price on shares of COMPASS Pathways in a report on Tuesday, September 10th. Canaccord Genuity Group dropped their price objective on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a research note on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a research report on Friday, August 23rd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, COMPASS Pathways presently has an average rating of “Buy” and a consensus price target of $47.40.
Check Out Our Latest Stock Report on COMPASS Pathways
About COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Further Reading
- Five stocks we like better than COMPASS Pathways
- What Are the FAANG Stocks and Are They Good Investments?
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What is a SEC Filing?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.